Mr President, particularly in the pharmaceuticals industry, of course, research and development are key when it comes to innovation and fighting diseases, which in turn, benefit EU citizens.
What action will the Commission take against pharmaceuticals companies that attempt to curtail parallel trading in the medicines sector?
Will it categorise such measures as anti-competitive?
